Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis (Q28073540)

main subject

basal ganglia disease

2 references

25 April 2019

17 September 2019

heterocyclic compound

1 reference

17 September 2019

1 reference

1 reference

25 January 2021

extrapyramidal symptoms

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Marina Danckaerts

series ordinal

2

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Martien Wampers

series ordinal

3

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marc De Hert

series ordinal

4

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

1 reference

September 2016

1 reference

1 September 2016

3 references

25 April 2019

17 September 2019

25 January 2021

5 references

25 April 2019

17 September 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

25 January 2021

30

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

807-818

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial

10 June 2020

copyright license

3 references

25 April 2019

17 September 2019

25 January 2021

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Atypical antipsychotics for psychosis in adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole for autism spectrum disorders (ASD)

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

A rating scale for drug-induced akathisia

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Treatment of Young People With Antipsychotic Medications in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

The use of antipsychotics in preschoolers: a veto or a sensible last option?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

The retrospective chart review: important methodological considerations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Treatment recommendations for extrapyramidal side effects associated with second-generation antipsychotic use in children and youth.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Antipsychotics in pediatric and adolescent patients: a review of comparative safety data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

An open-label study of aripiprazole in children with a bipolar disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Focus on aripiprazole: a review of its use in child and adolescent psychiatry

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

A methodology for conducting retrospective chart review research in child and adolescent psychiatry

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in children and adolescents: clinical experience

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Methodological strategies for the identification and synthesis of 'evidence' to support decision-making in relation to complex healthcare systems and practices

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

The efficacy of psychological, educational, and behavioral treatment. Confirmation from meta-analysis

29 September 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

29 September 2017

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole in children with Tourette's disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

A rating scale for extrapyramidal side effects

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4996892

2 June 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Open label aripiprazole in the treatment of youth with tic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

A prospective open-label study of aripiprazole in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

A retrospective chart review of intramuscular ziprasidone for agitation in children and adolescents on psychiatric units: prospective studies are needed

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit/hyperactivity disorder: an open clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

[Aripiprazole use in children and adolescent psychiatric patients].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Paediatric Atypical Antipsychotic Monitoring Safety (PAMS) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0367-Y

Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study

21 January 2018

1 reference

12 December 2020

An open-label trial of aripiprazole in the treatment of aggression in male adolescents diagnosed with conduct disorder

1 reference

12 December 2020

Aripiprazole in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

12 December 2020

10.1007/S40263-016-0367-Y

Identifiers

DOI

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27395403%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

PubMed publication ID

27395403

2 references